• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit

by Rakovina Therapeutics | Feb 4, 2026 | Uncategorized

DOWNLOAD Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent late-stage clinical setbacks in the field. Expanded Opportunity:...

Rakovina Therapeutics Announces Corporate Update Including up to $1.6 Million in New Financing, Leadership Appointments and Debt Restructuring

by Rakovina Therapeutics | Jan 28, 2026 | Uncategorized

Proposed $1.0 million Convertible Debenture and concurrent $600,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets ExecutionCurrent Convertible Debenture Maturity Extended; Further...

Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

by Rakovina Therapeutics | Jan 8, 2026 | Uncategorized

DOWNLOAD Vancouver, British Columbia, January 8, 2026 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery and Variational AI, a leader in...

Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

by Rakovina Therapeutics | Dec 22, 2025 | Uncategorized

DOWNLOAD Vancouver, British Columbia, December 17, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that...

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

by Rakovina Therapeutics | Dec 16, 2025 | Uncategorized

From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies Vancouver, British Columbia, December 10, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a...

Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update

by Rakovina Therapeutics | Dec 2, 2025 | Uncategorized

DOWNLOAD All dollar amounts reflected in Canadian dollars unless otherwise stated. Vancouver, British Columbia, December 1, 2025 – Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer...
« Older Entries
Next Entries »

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media